A novel multidrug regimen called ViPOR targeting survival pathways in diffuse large B-cell lymphoma showed significant responses in certain subtypes, with 38% of the cohort experiencing a complete response and tumors shrinking in 54% of participants. The regimen could be used before or instead of CAR-T therapy, offering a potentially curative option for patients with relapsed or refractory DLBCL. The ViPOR regimen, consisting of multiple targeted therapies, was found to be well-tolerated with minimal side effects. Researchers are planning a multicenter study to validate the results and exploring the addition of other drugs to enhance the effectiveness of the regimen.
Source link
Multidrug regimen could be ‘curative’ option for aggressive lymphoma
